| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on March 23, 2009
From the Divisions of Pulmonary and Critical Care (H.J.B., R.N., D.K., L.S., N.F.V.) and Cardiology (R.O.), Department of Medicine, and Department of Anatomy and Neurobiology (S.C.H.), Virginia Commonwealth University, Richmond; Department of Pulmonary Medicine, VU University Medical Center, Amsterdam, the Netherlands (H.J.B.); and Divisions of Cardiology (C.S.L.) and Pulmonary Sciences (J.M.M.), Department of Medicine, University of Colorado at Denver and Health Sciences Center, Aurora. * To whom correspondence should be addressed. E-mail: nvoelkel{at}mcvh-vcu.edu.
Background—The most important determinant of longevity in pulmonary arterial hypertension is right ventricular (RV) function, but in contrast to experimental work elucidating the pathobiology of left ventricular failure, there is a paucity of data on the cellular and molecular mechanisms of RV failure. Methods and Results—A mechanical animal model of chronic progressive RV pressure overload (pulmonary artery banding, not associated with structural alterations of the lung circulation) was compared with an established model of angioproliferative pulmonary hypertension associated with fatal RV failure. Isolated RV pressure overload induced RV hypertrophy without failure, whereas in the context of angioproliferative pulmonary hypertension, RV failure developed that was associated with myocardial apoptosis, fibrosis, a decreased RV capillary density, and a decreased vascular endothelial growth factor mRNA and protein expression despite increased nuclear stabilization of hypoxia-induced factor-1 Conclusion—These data brought into question the commonly held concept that RV failure associated with pulmonary hypertension is due strictly to the increased RV afterload.
Accepted on September 1, 2009
Chronic Pulmonary Artery Pressure Elevation Is Insufficient to Explain Right Heart Failure
Harm J. Bogaard MD, PhD,
. Induction of myocardial nuclear factor E2-related factor 2 and heme-oxygenase 1 with a dietary supplement (Protandim) prevented fibrosis and capillary loss and preserved RV function despite continuing pressure overload.
Related Article:
Circulation 2009 120: 1935-1936.
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2009 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |